Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 46 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
33 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Apotheek Dok Noord from Gent, company number BE0635613482, closed financial year 2025 with a result of € 118,621 after tax. For that financial year Apotheek Dok Noord recorded a gross margin of € 291,562 and equity of € 20,549. Compared with financial year 2024, the result moved from € 120,936 to € 118,621. The company is profitable. The buffer shrank hard: equity is 90 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 15, 2026.
€ 20,549
▼ 90% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 118,621
▼ 2% vs 2024
Profit after tax over the fiscal year.
€ 130,256
▼ 22% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 291,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
1.9
▲ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 92,004
▲ 5% vs 2024
€ 48,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 4,391
▼ 57% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2,197
▼ 95% vs 2024
Loans from banks and other lenders, long and short.
€ 49,363
▲ 11% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 39,849
▲ 14% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 219,230 | € 277,007 | € 290,938 | € 291,562 | |
| Profit after taxes | € 79,643 | € 111,890 | € 120,936 | € 118,621 | ▼ 2% |
| Equity | € 259,625 | € 168,615 | € 197,553 | € 20,549 | ▼ 90% |
| Total debts | € 297,156 | € 426,683 | € 280,619 | € 401,901 | ▲ 43% |
| Cash | € 236,321 | € 141,862 | € 167,947 | € 130,256 | ▼ 22% |
| Land & buildings | € 91,545 | € 68,768 | € 69,276 | € 50,606 | ▼ 27% |
| Retained profit | € 241,025 | € 150,015 | € 178,953 | € 1,949 | ▼ 99% |
| Dividend | € 18,232 | € 200,000 | € 87,800 | € 291,000 | ▲ 231% |
| Bank debt | € 142,662 | € 73,370 | € 47,216 | € 2,197 | ▼ 95% |
| Balance sheet total | € 556,781 | € 595,298 | € 478,172 | € 422,450 | ▼ 12% |
| Employees (FTE) | 1.9 | 1.8 | 1.8 | 1.9 | ▲ 0.1 |
Key figures of Apotheek Dok Noord, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Apotheek Dok Noord?
What happened at Apotheek Dok Noord in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 118,621 (▼ 2% vs 2024). Source: NBB ↗
- New establishment in Gent. KBO
- Eva Filliaert became a director. NBB
- Helena De Baets became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 79,643 profit in 2022 to € 118,621 profit in 2025.
Paid € 128,106 in corporate taxes since 2022.
Best year ever: 2024, with € 120,936 profit.
On average € 153,500 of value added per employee in 2025.
A new publication or filing at Apotheek Dok Noord? We notify you, reason included.
Follow Apotheek Dok NoordDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Apotheek Dok Noord are Eva Filliaert and Helena De Baets.
Directors
According to the 2025 annual accounts
Eva Filliaert
Director
since 2015
Helena De Baets
Director
since 2015
Establishments
Establishment units
Physical locations of this company
Dok-Noord 7
9000 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 33 companies are registered at this address.
All companies at this address →PLASSCHAERT
€ -33,439 gross margin · 2025
Club Sports Diffusion
€ 1.7 million gross margin · 2025
VASTGOED NOORD
€ 5.5 million gross margin · 2025
DE HOPDUVEL
€ 162,280 gross margin · 2025
HECTOR INVESTMENT
€ 2.8 million gross margin · 2025
+28 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Transip Mail
Hosting
COMBELL-AS, BE
DNS
TransIP DNS
Website info
Features
Security
Network
Details
- Company number
- 0635.613.482
- VAT number
- BE 0635.613.482
- Registered office
- Dok-Noord 7, 9000 Gent
- Names & denominations
- Apotheek Dok Noord
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 18 August 2015
- Peppol
- Active · Active since 15 Sept 2025
- Contact
- apotheekdoknoord.be
- Activities · NACE
Detailhandel in farmaceutische producten